Core Viewpoint - Rongchang Biologics (09995.HK) experienced a significant increase in stock price, rising over 5% to reach 96.45 HKD with a trading volume of 205 million HKD [2] Company Summary - Rongchang Biologics' stock price increased by 5.7% as of the latest report [2] - The current trading price is 96.45 HKD [2] - The total trading volume reached 205 million HKD [2]

Core Viewpoint - Rongchang Biologics (09995) shares rose over 5%, reaching a price of HKD 96.45, following the announcement of positive Phase III clinical trial results for Taitasip in treating systemic lupus erythematosus (SLE) published in the New England Journal of Medicine (NEJM) [1] Group 1: Clinical Trial Results - The Phase III trial achieved its primary endpoint, with 67.1% of patients in the Taitasip group showing significant improvement in disease activity, compared to 32.7% in the placebo group [1] - Taitasip is confirmed as a transformative B-cell therapy targeting BLyS/APRIL dual pathways, highlighting its advantages in treating SLE [1] Group 2: Disease Context and Treatment Landscape - Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect multiple organs and lead to irreversible damage, with over half of patients experiencing organ damage within 2-6 years of diagnosis [1] - Despite existing treatment options such as corticosteroids, antimalarials, immunosuppressants, and biologics, many patients still face challenges with disease activity, indicating a pressing need for new therapies [1] - Taitasip was approved for SLE treatment in China in March 2021 and was included in the national medical insurance drug list by the end of the same year, marking it as the world's first dual-target biologic new drug for SLE [1]

Core Viewpoint - Rongchang Biologics (09995) shares rose over 5%, currently up 5.7% at HKD 96.45, with a trading volume of HKD 205 million, following the announcement of positive Phase III clinical trial results for Taitasip in treating systemic lupus erythematosus (SLE) published in the New England Journal of Medicine (NEJM) [1][1][1] Group 1 - The Phase III trial achieved its primary endpoint, with 67.1% of patients in the Taitasip group showing significant improvement in disease activity compared to 32.7% in the placebo group [1][1][1] - Taitasip, a dual-target biologic therapy for B cells, is highlighted as a transformative treatment for SLE, showcasing its advantages in this therapeutic area [1][1][1] Group 2 - Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect multiple organs and lead to irreversible damage, with over half of patients experiencing organ damage within 2-6 years of diagnosis [1][1][1] - Despite existing treatment options such as corticosteroids, antimalarials, immunosuppressants, and biologics, many patients still face challenges with disease activity, indicating a pressing need for new therapies [1][1][1] - Taitasip was approved for SLE treatment in China in March 2021 and entered the national medical insurance drug list by the end of the same year, marking it as the world's first dual-target biologic new drug for SLE [1][1][1]

Core Viewpoint - Rongchang Bio (09995) has entered into an agreement with SPD Bank Yantai Branch to invest a total of RMB 5 billion in wealth management products, utilizing both idle self-owned funds and idle raised funds [1] Group 1 - The company will invest RMB 400 million of its idle self-owned funds in the wealth management products [1] - The company will also invest RMB 100 million of its idle raised funds in the wealth management products [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因依賴該等 內容而引致的任何損失承擔任何責任。 RemeGen Co., Ltd.* 榮 昌 生 物 製 藥（ 煙 台 ）股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：9995） 須予披露交易 購買理財產品 購買理財產品 本公司第二屆董事會第二十一次會議已於2025年3月27日，(1)審議批准了關 於使用自有資金進行現金管理的決議，根據該決議本公司可使用不超過人民幣 500.0百萬元額度的部分閒置自有資金購買保本型銀行理財產品，以及(2)審議批 准了關於使用閒置募集資金進行現金管理的決議，根據該決議本公司可使用不 超過人民幣140.0百萬元額度的部分閒置募集資金購買保本型銀行理財產品。 董事會宣佈，於2025年10月15日，本公司與浦發銀行煙台分行訂立浦發銀行理 財產品協議，據此本公司同意(1)以人民幣400.0百萬元的閒置自有資金向浦發銀 行煙台分行購買理財產品，以及(2)以人民幣100.0百萬元的閒置募集資金向浦發 銀 ...

Group 1 - Company Rongchang Bio (09995) announced an agreement with Pudong Development Bank Yantai Branch to purchase wealth management products [1] - The company will invest a total of RMB 5 billion, consisting of RMB 4 billion of idle self-owned funds and RMB 1 billion of idle raised funds [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因依賴該等 內容而引致的任何損失承擔任何責任。 RemeGen Co., Ltd.* 榮 昌 生 物 製 藥（ 煙 台 ）股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：9995） 須予披露交易 購買理財產品 購買理財產品 本公司第二屆董事會第二十一次會議已於2025年3月27日，(1)審議批准了關 於使用自有資金進行現金管理的決議，根據該決議本公司可使用不超過人民幣 500.0百萬元額度的部分閒置自有資金購買保本型銀行理財產品，以及(2)審議批 准了關於使用閒置募集資金進行現金管理的決議，根據該決議本公司可使用不 超過人民幣140.0百萬元額度的部分閒置募集資金購買保本型銀行理財產品。 董事會宣佈，於2025年10月15日，本公司與浦發銀行煙台分行訂立浦發銀行理 財產品協議，據此本公司同意(1)以人民幣400.0百萬元的閒置自有資金向浦發銀 行煙台分行購買理財產品，以及(2)以人民幣100.0百萬元的閒置募集資金向浦發 銀 ...

Core Viewpoint - The innovative drug sector experienced a significant rally, with the innovative drug index rising by 2.35% as of the midday close on October 15, 2025, driven by strong performances from various companies [1][2]. Group 1: Market Performance - The innovative drug index (886015.TI) closed at 1366.835, reflecting a gain of 2.35%, equivalent to an increase of 31.422 points [2]. - Notable stock performances included Guangshentang, which surged by 20% to 122.65, and several other companies such as Shutaishen and Anglikang, which saw gains of 14.4% and 10.01%, respectively [2][3]. Group 2: Upcoming Events - The European Society for Medical Oncology (ESMO) conference is set to take place from October 17 to 21, 2025, in Berlin, Germany, where significant clinical research results and data are expected to be disclosed [3][4]. Group 3: Business Development Opportunities - There is growing market anticipation for the release of clinical data from domestic innovative drugs and business development (BD) collaborations, with 83 overseas BD transactions recorded in the first eight months of 2025, totaling 845 billion yuan, marking a 62.81% increase compared to the entire year of 2024 [4]. Group 4: Company Earnings Forecast - Several innovative drug companies are expected to report strong earnings for the third quarter of 2025, with Shengnuo Bio projecting a net profit of 114 million to 140 million yuan, representing a year-on-year increase of 100.53% to 145.10% [5]. - Boteng Co. anticipates a net profit of 73.2 million to 88.2 million yuan, indicating a turnaround from losses, driven by a 17% to 21% increase in revenue [5]. Group 5: Industry Outlook - Analysts express optimism regarding the innovative drug sector, anticipating stabilization and rebound due to upcoming catalysts such as BD and medical insurance negotiations [6]. - Long-term trends indicate that the Chinese pharmaceutical industry has transitioned to new growth drivers, particularly in innovative drugs, which are expected to significantly contribute to the growth of Chinese pharmaceutical companies over the next 5 to 10 years [7].

Core Viewpoint - The innovative drug concept stocks experienced a significant surge in early trading on October 15, with several companies reaching their daily price limits and notable increases in stock prices [1]. Group 1: Stock Performance - Angli康 reached the daily limit up, indicating strong investor interest [1]. - Guangshengtang saw a rise of over 10%, with a notable increase of 14.41% in its stock price [2]. - Other companies such as Saili Medical, Shutaishen, Rongchang Bio, and Lianhuan Pharmaceutical also experienced substantial gains, contributing to the overall positive trend in the innovative drug sector [1]. Group 2: Notable Stock Increases - Guangshengtang (300436) reported a stock increase of 116.94%, with a rise of 14.41% [2]. - Pinlikang (002940) increased by 41.20%, with a rise of 10.01% [2]. - Saili Medical (603716) saw a 27.12% increase, with an 8.35% rise [2]. - Shutaishen (300204) experienced a 34.77% increase, with a 7.88% rise [2]. - Jimin Health (603222) rose by 10.64%, with a 6.72% increase [2]. - Lianhuan Pharmaceutical (600513) increased by 20.21%, with a 6.37% rise [2]. - Rongchang Bio (688331) saw a 97.06% increase, with a 6.31% rise [2]. - Zhendong Pharmaceutical (300158) increased by 6.95%, with a 5.95% rise [2]. - Kangchen Pharmaceutical (035500) rose by 48.68%, with a 4.91% increase [2]. - Maiwei Niwu-U (688062) saw a 46.58% increase, with a 4.86% rise [2].

Core Insights - Rongchang Biologics announced that its self-developed dual-target fusion protein innovative drug, Tai'axi, has received acceptance for its marketing application for the treatment of primary immunoglobulin A (IgA) nephropathy by the National Medical Products Administration (NMPA) and is included in the priority review process [1] - The application is based on positive results from the Phase III clinical study (Stage A) of Tai'axi for treating IgA nephropathy, which involved 318 adult patients receiving standard treatment [1] Group 1 - The Phase III clinical trial was a multi-center, randomized, double-blind, placebo-controlled study, where patients received a dosage of 240mg of Tai'axi via subcutaneous injection once a week [1] - The primary endpoint was achieved, showing that the Tai'axi group had a 55% reduction in the 24-hour urine protein-to-creatinine ratio (UPCR) compared to the placebo group after 39 weeks of treatment (P<0.0001) [1] - The drug demonstrated good tolerability and safety, with detailed data to be presented at an upcoming major international academic conference [1] Group 2 - IgA nephropathy is one of the most common primary glomerular diseases globally, with an estimated 10.16 million patients by 2030, including 2.37 million in China [2] - In China, IgA nephropathy patients account for approximately 54.3% of all renal biopsy cases, with 30% to 40% of these patients progressing to end-stage renal disease (ESRD), severely impacting their quality of life [2] - There is a significant unmet clinical need for effective treatments for IgA nephropathy, as current therapeutic options are very limited [2] - Besides IgA nephropathy, Tai'axi is also undergoing Phase II/III clinical studies for lupus nephritis and membranous nephropathy in China [2]